Cadila, Glenmark, Lupin Receive FDA Warnings Regarding Quality Concerns, Sun Pharma to Distribute Cancer Treatment Drugs in China Through AstraZeneca

Drug sector in India is plagued by quality concerns. Sun Pharma to distribute its cancer treatment drugs in China through AstraZeneca.

 

PHARMA

Cadila Healthcare, Glenmark Pharmaceuticals and Lupin receive FDA warnings.

The What: The US health care watchdog, Food and Drug Administration (FDA) has sent warning notices to three major Indian drugmakers - Cadila Healthcare, Glenmark Pharmaceuticals and Lupin.

 

What Does This Mean: A plant with a warning letter is barred from introducing new products in the US, stymieing the company’s ability to grow revenue in the world’s top pharmaceutical market.

 

Good To Know: Indian pharmaceutical factories collectively produce about 40 per cent of the American generic drug supply. BS

 

Cadila, Glenmark, Lupin Receive FDA Warnings Regarding Quality Concerns, Sun Pharma to Distribute Cancer Treatment Drugs in China Through AstraZeneca

 

Sun Pharma to distribute its cancer treatment drugs in China through Britain's AstraZeneca.

Indian drugmaker Sun Pharmaceutical has said that it would begin distributing some of its cancer treatment drugs in China through English-Swedish multinational pharmaceutical and biopharmaceutical company AstraZeneca.

 

 

Sun Pharma will be responsible for development, regulatory filings and manufacturing of the drugs covered in the deal, while AstraZeneca will exclusively promote and distribute the products in China. The agreement will have an initial tenure of 10 years.  Business Today

FIN.

(Don't want to miss out on these End Of Day Wrap Ups? Subscribe Now to our WhatsApp Feed and get the day's Top Business stories straight on your favourite messaging app.)